Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012.

Wysowski DK, Greene P.

Bone. 2013 Dec;57(2):423-8. doi: 10.1016/j.bone.2013.09.008. Epub 2013 Sep 21.

PMID:
24063946
[PubMed - indexed for MEDLINE]
2.

Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.

Martin KE, Yu J, Campbell HE, Abarca J, White TJ.

J Manag Care Pharm. 2011 Oct;17(8):596-609.

PMID:
21942301
[PubMed - indexed for MEDLINE]
Free Article
3.
4.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
[PubMed - indexed for MEDLINE]
5.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
[PubMed - indexed for MEDLINE]
6.

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.

Ito K, Blinder VS, Elkin EB.

J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27.

PMID:
22370313
[PubMed - indexed for MEDLINE]
Free Article
7.

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.

Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, Davies W.

Osteoporos Int. 2012 Apr;23(4):1415-24. doi: 10.1007/s00198-011-1729-4. Epub 2011 Jul 23.

PMID:
21786005
[PubMed - indexed for MEDLINE]
8.

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.

Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.

Clin Ther. 2007 Aug;29(8):1548-58. Review.

PMID:
17919538
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.

Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.

Curr Med Res Opin. 2007 Oct;23(10):2517-29.

PMID:
17825128
[PubMed - indexed for MEDLINE]
10.

Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.

Cosman F, Borges JL, Curiel MD.

Clin Ther. 2007 Jun;29(6):1116-27. Review.

PMID:
17692726
[PubMed - indexed for MEDLINE]
11.

Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate.

Yavropoulou MP, Hamdy NA, Papapoulos SE.

Osteoporos Int. 2013 Aug;24(8):2353-7. doi: 10.1007/s00198-013-2301-1. Epub 2013 Feb 23.

PMID:
23436076
[PubMed - indexed for MEDLINE]
12.

Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.

Bae SJ, Kim BJ, Lim KH, Lee SH, Kim HK, Kim GS, Koh JM.

J Bone Miner Metab. 2012 Sep;30(5):588-95. doi: 10.1007/s00774-012-0361-5. Epub 2012 May 19.

PMID:
22610063
[PubMed - indexed for MEDLINE]
13.

Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.

Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS.

Ann Pharmacother. 2011 Oct;45(10):1199-206. doi: 10.1345/aph.1Q239. Epub 2011 Sep 27.

PMID:
21954448
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.

Miller PD.

Clin Ther. 2005 Apr;27(4):361-76. Review.

PMID:
15922811
[PubMed - indexed for MEDLINE]
15.

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG.

Clin Ther. 2001 Sep;23(9):1409-21. Review.

PMID:
11589256
[PubMed - indexed for MEDLINE]
16.

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S.

J Bone Miner Res. 2013 Oct;28(10):2049-59. doi: 10.1002/jbmr.2058. Review.

PMID:
23907861
[PubMed - indexed for MEDLINE]
17.

Ibandronate: new options in the treatment of osteoporosis.

Adami S, Viapiana O.

Drugs Today (Barc). 2003 Nov;39(11):877-86. Review.

PMID:
14702133
[PubMed - indexed for MEDLINE]
18.

[Osteoporosis treatment in Portugal: trends and geographical variation].

Rocha O, Lunet N, Costa L, Barros H.

Acta Med Port. 2006 Sep-Oct;19(5):373-80. Epub 2007 Mar 8. Portuguese.

PMID:
17376323
[PubMed - indexed for MEDLINE]
Free Article
20.

An integrated approach: bisphosphonate management for the treatment of osteoporosis.

Owens G, Jackson R, Lewiecki EM.

Am J Manag Care. 2007 Dec;13 Suppl 11:S290-308; quiz S309-12. Review.

PMID:
18095779
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk